Canada markets open in 3 hours 34 minutes

TRIB May 2024 2.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.10000.0000 (0.00%)
As of 11:44AM EDT. Market open.
Full screen
Previous Close0.1000
Open0.1000
Bid0.0000
Ask0.0500
Strike2.50
Expire Date2024-05-17
Day's Range0.1000 - 0.1000
Contract RangeN/A
Volume1
Open Interest1
  • GlobeNewswire

    Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

    DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company’s recently acquired continuous glucose monitor (CGM) biosensor technology. Under this collaboration, Trinity Biotech will provide a pool of unique multi-p

  • GlobeNewswire

    Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales

    DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million. The Company has successfully scaled up production to meet the increased demand for its rapid HIV tests. A

  • GlobeNewswire

    Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

    DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM s